Evotec SE (EVO) Total Non-Current Liabilities (2009 - 2026)

Evotec SE (EVO) reported Total Non-Current Liabilities of $605063.6 for Q1 2026, down 14.89% on a YoY basis from $710906.6 in Q1 2025, and down 2.32% sequentially from $619465.5 in Q4 2025.

Evotec SE (EVO) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends

Evotec SE (EVO) has 9 years of Total Non-Current Liabilities data on file, last reported at $605063.6 in Q1 2026.

  • For the quarter ending Q1 2026, Total Non-Current Liabilities fell 14.89% year-over-year to $605063.6; the trailing twelve-month figure through Mar 2026 stood at $605063.6 (down 14.89% YoY), and the FY2025 full-year result was $619465.5, down 99.91% from the prior year.
  • Total Non-Current Liabilities slipped to $605063.6 in Q1 2026, from $619465.5 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $747.2 million in Q4 2022 to a low of $404.41 in Q2 2022.
  • A 5-year average of $177.4 million and a median of $699141.1 in 2025 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities climbed 22.55% in 2022 and slumped 99.91% in 2025, its largest moves.
  • Tracing EVO's Total Non-Current Liabilities over 5 years: stood at $747.2 million in 2022, then slipped by 3.81% to $718.7 million in 2023, then fell by 8.5% to $657.6 million in 2024, then tumbled by 99.91% to $619465.5 in 2025, then dropped by 2.32% to $605063.6 in 2026.
  • Business Quant data shows EVO's Total Non-Current Liabilities at $605063.6 in Q1 2026, $619465.5 in Q4 2025, and $699208.3 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Evotec SE 351.60 Mn 351.08 Mn - 605,063.60

Historic Data

Download Data
DateValue
Mar 31, 2026 605,063.60
Dec 31, 2025 619,465.55
Sep 30, 2025 699,208.34
Jun 30, 2025 655,728.40
Mar 31, 2025 710,906.63
Dec 31, 2024 657.61 Mn
Sep 30, 2024 756,366.83
Dec 31, 2023 718.71 Mn
Dec 31, 2022 747.19 Mn
Sep 30, 2022 699,073.90
Jun 30, 2022 404.41
Mar 31, 2022 601,058.99
Dec 31, 2021 609.69 Mn
Sep 30, 2021 614,870.98
Dec 31, 2020 631.22 Mn
Sep 30, 2010 23,121.53
Jun 30, 2010 8,710.96
Mar 31, 2010 10.40
Dec 31, 2009 12,798.86
Aug 31, 2009 -93.19